Wencke Walter

1 Introduction In the WHO HAEM-5 classification, the category “Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions” comprises cases with PDGFRB rearrangements, of which ETV6 is the most common partner gene, leading to an ETV6::PDGFRB fusion gene resulting from the reciprocal translocation t(5;12)(q32;p13) [1]. These cases often present with eosinophilia and are exquisitely sensitive to imatinib, leading to durable complete remissions and excellent long-term survival.

Risk stratification is the backbone of clinical decision-making for patients with haematological malignancies. Models currently used in routine clinical practice often rely on static rules, conventional statistics and expert consensus. While pragmatic and accessible, these models fail to capture the complex biological interactions and patient heterogeneity, especially as data dimensionality grows given the availability of more comprehensive molecular analysis.

Abstract In the rapidly evolving field of hematology, the diagnosis of leukemias and lymphomas poses major challenges, despite significant genetic advancements. Although established diagnostic methods comprise a multidisciplinary approach and are considered gold standard, in some cases they fall short in conclusively identifying hematological neoplasms.